Israel Firm Seeks Funding For More Trials Of Flesh-Eating Bacteria Drug
This article was originally published in PharmAsia News
Executive Summary
Israel's Atox Bio plans a fund-raising effort to cover the expense of more Phase II trials of its drug to treat severe infections of flesh-eating bacteria and deadly viruses.